News
POAI
1.316
+2.02%
0.026
Weekly Report: what happened at POAI last week (0415-0419)?
Weekly Report · 2d ago
Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers
Seeking Alpha · 5d ago
Weekly Report: what happened at POAI last week (0408-0412)?
Weekly Report · 04/15 12:04
Weekly Report: what happened at POAI last week (0401-0405)?
Weekly Report · 04/08 12:10
Weekly Report: what happened at POAI last week (0325-0329)?
Weekly Report · 04/01 12:07
Predictive Oncology GAAP EPS of -$3.48, revenue of $1.78M
Earnings News Predictive Oncology GAAP EPS of -$3.48, revenue of $1.78M (+17.9% Y/Y). Net cash used in operating activities was $13.19M in 2023, compared to $12.37M in 2022.
Seeking Alpha · 03/29 05:12
Predictive Oncology Q4 EPS $(0.85) Up From $(2.00) YoY, Sales $335.03K Down From $363.47K YoY
Predictive Oncology reported quarterly losses of $0.85 per share. The company reported $335.03 thousand in sales for the quarter. This is a 7.82 percent decrease over sales of $363.47 thousand in the same period last year.
Benzinga · 03/29 04:59
POAI Stock Earnings: Predictive Oncology Reported Results for Q4 2023
Predictive Oncology reported results for the fourth quarter of 2023. The company reported earnings per share of -85 cents and revenue of $335,032. Predictive oncology is a biopharmaceutical company with a focus on cancer treatment and research.
Investorplace · 03/29 03:52
Predictive Oncology Inc: Annual report
Press release · 03/29 02:11
*Predictive Oncology 2023 Loss/Shr $3.48 >POAI
Dow Jones · 03/28 21:53
*Predictive Oncology 2023 Rev $1.8M >POAI
Dow Jones · 03/28 21:53
Press Release: Predictive Oncology Reports Year -2-
The Company disclaims any intent or obligation to update these forward-looking statements. The Company's financial results are based on the condensed consolidated statements of assets and liabilities as of December 31, 2013. The Company has no plans to update any of these statements. The company's stock is trading on the New York Stock Exchange.
Dow Jones · 03/28 21:28
Press Release: Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT. The company reported a net loss of approximately $14 million for the year ended December 31, 2023. Company is leveraging its proprietary artificial intelligence and machine learning capabilities to accelerate oncologic drug discovery and enable drug development.
Dow Jones · 03/28 21:28
Weekly Report: what happened at POAI last week (0318-0322)?
Weekly Report · 03/25 12:10
Weekly Report: what happened at POAI last week (0311-0315)?
Weekly Report · 03/18 12:08
Weekly Report: what happened at POAI last week (0304-0308)?
Weekly Report · 03/11 12:03
Weekly Report: what happened at POAI last week (0226-0301)?
Weekly Report · 03/04 12:07
Weekly Report: what happened at POAI last week (0219-0223)?
Weekly Report · 02/26 12:26
Weekly Report: what happened at POAI last week (0212-0216)?
Weekly Report · 02/19 12:29
Weekly Report: what happened at POAI last week (0205-0209)?
Weekly Report · 02/12 12:14
More
Webull provides a variety of real-time POAI stock news. You can receive the latest news about Predictive Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About POAI
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.